NMD Pharma
Biotech · Aarhus, DK
ClC-1 chloride-channel inhibitors to restore muscle function in neuromuscular diseases
Funding history
| Date | Round | Amount |
|---|
| Nov 2023 | Series B Aarhus biotech NMD Pharma raised a 75M EUR Series B led by Jeito Capital to fund three Phase 2 trials of its lead neuromuscular drug NMD670. | $81M |
Investors
INKEF CapitalJeito CapitalLundbeckfonden BioCapitalNovo HoldingsRoche Venture Fund
Similar companies in Biotech
Explore funding flow on EquityFlow →